Where NAC is permitted, and what the file must show
N-acetyl-L-cysteine is regulated differently in each market. The EU has no harmonised supplement listing and leaves the food-or-medicine question largely to Member States. The US FDA has exercised enforcement discretion since 2022 and published a proposed rule in November 2026 that would, if finalised, confirm NAC is not excluded from the dietary supplement definition. Great Britain applies retained food law and its own novel-food and claims registers, while Northern Ireland follows the EU regime; permission, contaminants, labelling and claims remain separate checks.
Permission, contaminant limits, label wording and claims are four separate checks, and NAC answers them differently in the EU, the US and the UK.
The four checks
Selling an NAC lot raises four questions that are often conflated: is the substance permitted, and on what basis; which contaminant ceiling applies at the daily dose; does the label declare the form correctly; and is the statement an authorised claim, a structure/function statement, or not allowed at all? The answers do not travel together. A form accepted in one country can be a medicine in another, and a finished-product ceiling cannot be pasted onto the raw material. The current legal text in the destination market decides.
European Union
Directive 2002/46/EC harmonises food supplements, and its Annex I includes amino acids among the permitted substance categories. It does not contain an EU positive list of individual amino acids, so NAC is regulated mainly through Member State law and the general food rules. In practice the substance has a dual status: a licensed medicine in several Member States and a food supplement in others, with classification turning on dose, presentation and claims. The destination country is the first check, because a Member State may restrict a supplement that another accepts.
National assessments have also set guidance: a 2015 Spanish assessment accepted 300 mg per day of NAC from food supplements, a national position rather than an EU maximum. Record the novel-food question for the specific use. Labelling follows Regulation (EU) No 1169/2011 and the supplement particulars in Directive 2002/46/EC; claims follow Regulation (EC) No 1924/2006. NAC has no EU nutrient reference value, so no percentage NRV can be declared, and the claim register contains no authorised NAC claim as of this review. The EU regulatory note expands the framework.
United States
US law asks whether NAC is a lawful dietary ingredient under section 201(ff) of the Federal Food, Drug, and Cosmetic Act. The FDA has regarded NAC as excluded because it was approved as a drug before DSHEA, and since 2022 a final guidance has applied enforcement discretion to NAC products labelled as dietary supplements. In November 2026 the FDA published a proposed rule, 91 FR 73717, that would provide by regulation that NAC is not excluded from the dietary supplement definition. As of this review the rule is proposed, not final, so the file records both the guidance and the rulemaking status.
A supplement label follows the Supplement Facts panel in 21 CFR 101.36: serving size, amount of NAC per serving and the ingredient name. There is no Daily Value for NAC, so the panel carries no percentage. A structure/function statement must be truthful, not misleading and substantiated, and must sit beside the DSHEA disclaimer in 21 CFR 101.93; the marketer notifies the FDA within 30 days of first marketing it.
There is no federal maximum for lead in supplements. California's Proposition 65 sets a maximum allowable dose level of 0.5 µg/day for lead, calculated from the daily dose. The US regulatory note sets out the framework.
The contaminant table
| Element | EU | US | UK |
|---|---|---|---|
| Lead | 3.0 mg/kg | No federal maximum specific to supplements; Proposition 65 may apply | Retained limits; check the current GB text |
| Cadmium | 1.0 mg/kg | Check federal and state law | Retained limits; check the current GB text |
| Mercury | 0.10 mg/kg | Check federal and state law | Retained limits; check the current GB text |
| Arsenic | Not harmonised; a Member State limit is possible | Check federal and state law | Retained limits; check the current GB text |
The EU column is written for the supplement as sold, not the raw material. The catalog specification sets Pb ≤3, As ≤2, Cd ≤1 and Hg ≤0.1 mg/kg, a raw-material gate whose adequacy depends on the daily dose and the share of the formula. Arsenic has no harmonised EU number for supplements, so the buyer sets one. The UK column is a prompt: GB retained and amended EU contaminant law, so confirm the current text.
Claims and labelling
The EU claim register under Regulation (EU) No 432/2012 authorises only the listed wording and conditions. No NAC entry appears there as of this review, and NAC has no NRV to anchor a “source of” nutrition claim; a disease claim is outside the regulation altogether. In the US, a structure/function statement is written and substantiated by the brand and carries the DSHEA disclaimer; it is not an FDA approval and cannot describe a disease or a medicinal use. In the UK, the GB nutrition and health claims register performs the same role, and no NAC claim appears there as of this review.
The label should name the form: N-acetyl-L-cysteine, not L-cysteine or an abbreviation alone. NAC has no EU NRV or US Daily Value, so the panel declares the amount per portion or serving without a percentage. A product that also contains cysteine or cystine must declare each form separately; the three names are not interchangeable. Nothing on this page is a claim for the ingredient.
The document pack
A complete lot file usually contains:
- A lot COA covering assay by HPLC on the dried basis, specific rotation, thiol and infrared identity, water, residue, pH, mesh, metals and microbiology.
- A TDS, a purchase specification naming the form and mesh, and a 16-section SDS.
- Allergen, GMO, origin, residual-solvent and animal-derived input statements.
- An elemental-impurity report against the destination limit at the intended dose.
- Stability data for the grade and pack, and the storage condition on the TDS.
- A US basis memo recording the 2022 guidance and the 2026 proposed rule, an EU or UK market note, and an independent COA where required.
Every document should carry the lot number. A generic TDS and a lot-specific COA are not a matched pair unless form, mesh and pack agree.
What to check before the first order
Six questions settle the file:
- Which market will sell the product, and which legal route is documented there?
- Does the COA name N-acetyl-L-cysteine and report rotation and thiol identity, not only the assay?
- Are the metal figures below the destination ceiling at the actual daily dose?
- Does the label name the form, omit a percentage NRV or Daily Value, and carry the required particulars?
- Is every claim inside the authorised wording or a properly disclaimed structure/function statement?
- Is the lot file complete and lot-coded, with the food-or-medicine borderline recorded?
The COA page shows the parameters the file has to support, and the identity page explains how the form is proved. The product hub carries the catalog specification, and the quality page shows how the lot file is assembled. The UK and EU notes expand the market positions.
Related documents
Send the specification you intend to use — grade, quantity and destination market — and we will reply with the batch COA, the technical data sheet and a quotation.
Request a quotation